Skip to content

Investigating The Effect of Aerobic Exercise on Hematopoietic Stem Cells Engraftment in Patients Undergoing Autologous Hematopoietic Cell Transplantation

The Effect of Aerobic Exercise on Promoting Hematopoietic Stem Cells Engraftment in Patients Undergoing Autologous Hematopoietic Cell Transplantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220708055415N1
Enrollment
40
Registered
2023-02-25
Start date
2023-02-20
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Multiple myeloma. Condition 2: non-Hodgkin lymphoma. Multiple myeloma Other specified and unspecified types of non-Hodgkin lymphoma

Interventions

Intervention 1: Intervention group: After hospitalization and before transplantation, the patients are first subjected to the mobilization and release of stem cells for about 7 days through the inject

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
22 Years to 62 Years

Inclusion criteria

Inclusion criteria: Malignant Disease with Indication of HSCT, Transplantation of Peripheral Blood Stem Cells by Autologous Method, Age between 22 and 62 Years, Performing an Exercise Test Under the Supervision of a Cardiologist to Check the Patient's Cardiovascular Condition. Karnofsky Performance (KPS) with Scores Above 90 Suitable Functional Capacity of the Patient for Walking on the Treadmill. No History of Chronic Diseases such as High Blood Pressure, Severe Heart Failure, Respiratory Disease and Allergies, Diabetes, Kidney Failure, and Orthopedic Problems No History of Treatment and Radiotherapy

Exclusion criteria

Exclusion criteria: Hemoglobin Below Eight Micrograms Per Liter Decrease in Platelets Below 50,000 Symptoms of Fever, Neutropenia, Bleeding, Nausea

Design outcomes

Primary

MeasureTime frame
White blood cell count. Timepoint: Before and after transplantation. Method of measurement: Analyzer device, model Hitachi 912 made by Roche, Germany.;Hemoglobin count. Timepoint: Before and after transplantation. Method of measurement: Analyzer device, model Hitachi 912 made by Roche, Germany.;Platelet count. Timepoint: Before and after transplantation. Method of measurement: Analyzer device, model Hitachi 912 made by Roche, Germany.

Secondary

MeasureTime frame
The number of platelet units injected. Timepoint: After transplantation. Method of measurement: Counting the number of platelet units injected.;CD34+ hematopoietic progenitor cells. Timepoint: Before and after transplantation. Method of measurement: flow cytometry (Attune NXT, USA Country).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoomeh Kamyabnia

Islamic Azad University

m_kamiyab@yahoo.com+98 21 4689 6000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026